Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Ovarian Cancer Clinical Trial

Official title:

Phase I Study of Capecitabine (Xeloda) and Radiation Therapy in Patients With Locally Advanced Cervical and Pelvic Malignancies

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00118300
• Other study ID #: CASE9804
• Secondary ID: P30CA043703CASE-
• Status: Withdrawn
• Phase: Phase 1
• First received: July 8, 2005
• Last updated: July 7, 2011
• Start date: April 2005

Study information

• Verified date: July 2011
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with radiation therapy in treating patients with locally advanced cervical cancer or other pelvic cancer.

Description:

OBJECTIVES:

Primary

• Determine the maximum tolerated dose and dose-limiting toxicity of capecitabine when given in combination with pelvic external beam radiotherapy and intracavitary brachytherapy in patients with primary or recurrent locally advanced cervical cancer or other pelvic malignancy.

Secondary

• Determine the clinical anti-tumor response in patients treated with this regimen.

• Determine adverse clinical sequelae in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of capecitabine.

Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5 and receive 1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8. Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.

NOTE: *No external beam radiotherapy is administered on the day of HDR brachytherapy. If the majority of external beam radiotherapy has been administered, HDR brachytherapy may be administered in 2 applications per week (separated by at least 72 hours) in order to complete all treatment by week 8.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.

After completion of study treatment, patients are followed at 1 month, every 3 months for 1 year, every 6 months for 2 years, and then annually for 2 years.

PROJECTED ACCRUAL: Approximately 4-24 patients will be accrued for this study within 2-12 months.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed cervical cancer or other pelvic malignancy, including vaginal, endometrial, or ovarian cancer

• Primary or recurrent disease

• Locally advanced disease, defined as the following:

• Stage IB2-IVA (for cervical or vaginal cancer)

• Any non-extra pelvic metastatic stage (for endometrial or ovarian cancer)

• Not amenable to curative surgical resection alone

• Bidimensionally measurable or clinically evaluable disease

• Refused or ineligible for weekly IV cisplatin chemotherapy due to renal insufficiency, prior platinum adverse sensitivity, pre-existing neuropathy, or concurrent co-morbid illness

• No histologically confirmed or clinically suspicious (= 1 cm) para-aortic lymphadenopathy

• No brain metastases or primary brain tumors

PATIENT CHARACTERISTICS:

Age

• 18 and over (80 and under for second and third dose-escalation levels)

Performance status

• GOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count = 1,500/mm^3

• Absolute granulocyte count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• Hemoglobin = 10.0 g/dL

Hepatic

• Bilirubin = 1.5 mg/dL

• AST and ALT < 2 times upper limit of normal

Renal

• See Disease Characteristics

• Creatinine normal OR

• Creatinine clearance = 30 mL/min*

• No proteinuria or clinically significant impaired renal function NOTE: *Creatine clearance testing required in patients > 60 years of age

Cardiovascular

• No symptomatic New York Heart Association class III or IV congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• No uncontrolled hypertension

Gastrointestinal

• Able to swallow oral medication

• No bowel obstruction

• No malabsorption illness

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No known hypersensitivity to capecitabine or fluorouracil

• No ongoing or active infection

• No other uncontrolled illness

• No psychiatric illness or social situation that would preclude study compliance

• No other active invasive malignancy

• Prior malignancy in remission for = 6 months that is not currently being treated allowed

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Recovered from prior chemotherapy

• At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)

• Prior chemotherapy for a non-gynecologic malignancy or in the adjuvant setting allowed

• No prior capecitabine

Endocrine therapy

• Prior adjuvant hormonal therapy allowed

Radiotherapy

• Recovered from prior radiotherapy

• At least 4 weeks since prior radiotherapy

• Prior radiotherapy for a non-gynecologic malignancy allowed

• No prior low abdominal or pelvic radiotherapy

Surgery

• Not specified

Other

• At least 3 weeks since prior investigational anticancer agents and recovered

• No prior anticancer treatment that contraindicates study therapy

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Uterine Cervical Neoplasms
• Vaginal Cancer
• Vaginal Neoplasms

Intervention

Drug:
• capecitabine
Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.

Radiation:
• brachytherapy
1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.
• radiation therapy
Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.

Locations

Country	Name	City	State
United States	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center	Cleveland	Ohio
United States	Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose		weekly	Yes
Primary	Disease response measured prior to brachytherapy and at 1 month after completion of study treatment		1 month after completion of study treatment	No
Primary	Toxicity as measured by CTC v 3.0 weekly		weekly	Yes

External Links

•   Clinical trial summary from the National Cancer Institute's PDQ® database